2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, AML, Translational Research, CML, Study Population, Human, Animal Model
PAPER

4977 DNMT3A and TET2 mutations impose opposing hox cluster methylation states that direct NPM1c AML toward stem-like or mature monocytic disease

Elmira Khabusheva, PhD, Xiaoyan Zhang, MS2, Josephine De La Fuente, MS3, Nayara Alcantara-Contessoto4, Evdokiia Potolitsyna5, Jacey Rodriguez Pridgen6, Anna Guzman7, Sarah Waldvogel, PhD8, Brianda Gill9, Michaela Koltz10, Gandhar Datar11, Hongyuan Zhang12, Katharina Wohlan, PhD13, Alexis Quezada14, Venkatasubramaniam Sundaramurthy15, Taishi Yonezawa, PhD16, Steven Kornblau, MD17, Joshua Riback18, Margaret Goodell, PhD19
1 Baylor College of Medicine, Houston, Texas, United States
2 Baylor College of Medicine, Houston, Texas, United States
3 Baylor College of Medicine, Houston, Texas, United States
4 Baylor College of Medicine, Houston, Texas, United States
5 Baylor College of Medicine, Houston, Texas, United States
6 Baylor College of Medicine, Houston, Texas, United States
7 Baylor College of Medicine, Houston, Texas, United States
8 Baylor College of Medicine, Houston, Texas, United States
9 Baylor College of Medicine, Houston, Texas, United States
10 Baylor College of Medicine, Houston, Texas, United States
11 Baylor College of Medicine, Houston, Texas, United States
12 Baylor College of Medicine, Houston, Texas, United States
13 Baylor College of Medicine, Houston, Texas, United States
14 Baylor College of Medicine, Houston, Texas, United States
15 Baylor College of Medicine, Houston, Texas, United States
16 Baylor College of Medicine, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, United States
18 Baylor College of Medicine, Houston, Texas, United States
19 Baylor College of Medicine, Houston, Texas, United States

Introduction: Mutant nucleophosmin (NPM1c) is the most frequent genetic lesion in de novo adult acute myeloid leukemia (AML) and typically arises in stem and progenitor cells already carrying mutations in the epigenetic regulators DNMT3A or TET2. DNMT3A and TET2 oppositely impact DNA methylation, and their mutations are associated with distinct NPM1c AML phenotypes. We recently showed that NPM1c drives characteristic HOX gene expression, MENIN-inhibitor sensitivity, and in vivo expansion through the formation of aberrant nuclear condensates (“C-bodies”) enriched for transport proteins and the KMT2A/MENIN complex. We hypothesized that loss of DNMT3A and TET2 function establishes opposing methylation and chromatin states at NPM1c-associated genes, and that C-bodies exploit these states differently, steering NPM1c-driven transformation toward divergent phenotypes and therapeutic response.

Methods: Bone marrow cells from an Npm1c-inducible mouse line with or without Dnmt3a-R878H (Dnmt3aMUT) or Tet2 heterozygous loss (Tet2HET) were transplanted with the WT competitor cells (10:90 ratio) into lethally irradiated recipients. Bone marrow and peripheral blood were analyzed by spectral flow cytometry; transcriptome with RNA-seq; DNA methylation by enzymatic methyl-sequencing (EM-seq); KMT2A and MENIN chromatin enrichment by CUT&RUN; and C-body composition by immunofluorescence and live imaging in CRISPR-edited cell lines. DNMT3A (R882C) correction and TET2 knockout (TET2KO) in OCI-AML3 (DNMT3AMUT NPM1c AML) were performed by CRISPR/Cas9. MENIN-inhibitor sensitivity was assessed by monocytic differentiation (CD11b/CD14). Response to inflammatory stimuli (LPS/nigericin) was measured by immunoblotting for cleaved gasdermin D. DNA for EM-seq analysis was isolated from the peripheral blood of patients with NPM1c AML.

Results: Both Dnmt3aMUT/Npm1c and Tet2HET/Npm1c double mutants showed increased myeloid output and expansion of myeloid-biased (MPP3), and megakaryocytic (MkP) stem and progenitor cells (HSPCs) compared to Npm1c alone. However, only Dnmt3aMUT cooperated with Npm1c to induce Hoxa9/10 expression and sustain long-term multilineage reconstitution (45% vs <10% for Npm1c alone) for 22 weeks, whereas Tet2HET/Npm1c cells were myeloid-restricted and were progressively outcompeted in secondary transplantation assays, indicating exhausted self-renewal. Introducing mutant Nras into both genotypes generated AML with shorter latency in the Dnmt3aMUT background (30 vs 60 days). Dnmt3aMUT AML accumulated myeloid HSPCs and inflammatory monocytes, whereas Tet2HET AML lacked HSPCs and was largely monocytic. This distinction was mirrored in published datasets: DNMT3AMUT NPM1c AML showed a mixed progenitor-monocytic transcriptomic signature, while TET2MUT NPM1c AML showed a mature monocytic program.

In AML cell lines, we found that NPM1c formed nuclear condensates independent of DNMT3A/TET2 mutations, but their chromatin targets and resulting transcription programs diverged. In DNMT3AMUT NPM1c AML, C-body components were enriched at hypomethylated loci across two distinct programs – HOX cluster/stem cell identity and inflammatory signaling program genes. DNMT3A correction restored methylation, displaced KMT2A, and silenced HOX and inflammatory pathways, whereas subsequent TET2 knockout reinforced HOX downregulation. Consistent with these findings, primary human NPM1c AML samples showed genotype-dependent HOX cluster methylation, with higher methylation in TET2MUT than DNMT3AMUT cases. Functionally, this dictated KMT2A-dependent vulnerabilities: DNMT3AMUT NPM1c AML was uniquely sensitive to acute inflammatory stimuli and MENIN inhibition, a dependency reproduced across murine Npm1c models with distinct Dnmt3a and Tet2 genotypes, whereas sensitivity to NPM1c degradation was conserved.

Conclusions: DNMT3A and TET2 mutations prime NPM1c leukemia in opposite directions. DNMT3A mutation leaves HOX and inflammatory program loci hypomethylated, where C-bodies engage chromatin in a KMT2A-dependent manner to sustain an inflammation-primed mixed stem-like/monocytic state that retains MENIN-inhibitor sensitivity. TET2 loss instead restrains the HOX program, yielding mature monocytic disease with limited self-renewal capacity. Thus, DNA methylation state shapes the chromatin programs engaged by NPM1c C-bodies, promoting either a stem-like/monocytic or mature monocytic leukemic state with divergent inflammatory signaling and MENIN-inhibitor responses.

Elmira Khabusheva, PhD: No relevant conflicts of interest to declare.